Navigation Links
Research consortium at CHLA receives $410,000 to study leukemia and lymphoma
Date:7/20/2010

LOS ANGELES (July 19, 2010) J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.

"Both ALL and AML are cancers of the blood and bone marrow, with ALL being the most common cancer occurring in children," explains Dr Bubbers. "These diseases begin when a single cell changes from a normal cell to a cancer cell. Patients receive treatment chemotherapy and/or radiation with the hope of achieving remission. But sometimes that doesn't happen, or the remission doesn't last."

A child is in remission when he or she is not showing any signs or symptoms of disease. But sometimes the cancer cells return. This condition is called relapse. Other patients undergo treatment but not all the cancer cells are gone from their body. In this case, the patient has refractory disease. When a child has relapsed or refractory disease, different treatments may be required.

The TACL consortium is studying a new alternative treatment for these patients. Gene-targeted therapy, a type of personalized medicine, is based on the specific type of chromosomal changes occurring in a patient's cells. Certain genetic mutations, those of FLT3 and c-Kit, are associated with a particularly poor prognosis. This multi-center study will use a new drug that has been expressly optimized to inhibit FLT3 and c-Kit and has been effective in treating adults with these diseases. The goal of the phase I study is to determine a safe and biologically-active dose in young patients.


'/>"/>

Contact: Ellin Kavanagh
ekavanagh@chla.usc.edu
323-361-8505
Children's Hospital Los Angeles
Source:Eurekalert

Page: 1

Related medicine news :

1. Concordia researcher leads study that finds kids reduce physical activity for heart patients
2. U of Us Janice Morse inducted into International Nurse Researcher Hall of Fame
3. Researchers Use Ecstasy to Treat PTSD
4. Licensed Florida Tech research makes lab work easier
5. New research finds major activation themes in denture-stomatitis
6. UC San Diego researchers find cause of metabolic disease -- and possible cure
7. Researchers cut years from drug development with nanoscopic bead technology
8. New research explores relief for xerostomia cancer patients
9. 5 awarded ASTRO research grants
10. Lu receives grant from Research to Prevent Blindness organization
11. NIH expands food allergy research program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: